Current international initiatives in antiphospholipid antibody testing

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 4, 2012, Pages 360-374

  Willis, Rohan ^a,b   Harris, E Nigel ^b   Pierangeli, Silvia S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

anti glycoprotein I antibodies; anticardiolipin antibodies; antiphospholipid antibodies; lupus anticoagulant; standardization

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EY2C9; MONOCLONAL ANTIBODY HCAL; PHOSPHOLIPID ANTIBODY; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; DILUTE ACTIVATED PARTIAL THROMBOPLASTIN TIME; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTHROMBIN TIME; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; STANDARDIZATION; THROMBIN TIME; THROMBOSIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; FEMALE; HUMANS; INTERNATIONAL AGENCIES; LUPUS COAGULATION INHIBITOR; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84861342450     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1313564     Document Type: Review

References (121)

1. Wilson WA, Gharavi AE, Koike T., et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum: 1999; 42 1309 1311 (Pubitemid 30265586)
2. Miyakis S, Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 2 295 306
3. Reber G, Schousboe I, Tincani A., et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost: 2002; 88 1 66 73 (Pubitemid 34752269)
4. Harris EN, Gharavi AE, Patel SP, Hughes GRC. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol: 1987; 68 1 215 222 (Pubitemid 17044795)
5. Harris EN. The second international anticardiolipin standardization workshop: the Kingston Anticardiolipin Antibody Study (KAPS) group. Am J Clin Pathol: 1990; 94 4 476 484 (Pubitemid 20316579)
6. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol: 1994; 101 5 616 624
7. Pierangeli SS, Stewart M, Silva LK, Harris EN. Report of an anticardiolipin wet workshop during the VIIth International Symposium on antiphospholipid antibodies. J Rheumatol: 1998; 25 156 162
8. Wong RCW, Wilson RJ, Pollock W, Steele R, Gillis D. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology: 2004; 36 2 174 181 (Pubitemid 38507880)
9. Tincani A, Allegri F, Sanmarco M., et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinationsa cooperative project of the European Antiphospholipid Forum. Thromb Haemost: 2001; 86 2 575 583 (Pubitemid 32743269)
10. Wong RCW, Wilson RJ, Pollock W, Steele RH, Gillis D. Anti-cardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology: 2004; 36 2 174 181 (Pubitemid 38507880)
11. Goudemand J, Caron C, De Prost D., et al. Evaluation of sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Socit Franaise de Biologie Clinique and for the Groupe d'Etudes sur I'Hmostase et la Thrombose. Thromb Haemost: 1997; 77 2 336 342 (Pubitemid 27084927)
12. Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-I (ISLA-1). Thromb Haemost: 1990; 64 3 478 484
13. Hemostasis Committee of the Societe Francaise de Biologie Clinique Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using different clotting assays on a panel of 78 samples. Hemostasis Committee of the "Socit Franaise de Biologie Cliniqueo" Thromb Res: 1992; 66 4 349 364
14. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost: 1997; 77 5 934 937 (Pubitemid 27239117)
15. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human 2-glycoprotein I. Thromb Haemost: 1999; 81 6 929 934 (Pubitemid 29312710)
16. Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa MC.; Standardization group of the European Forum on Antiphospholipid Antibodies Proposals for the measurement of anti-2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost: 2004; 2 10 1860 1862 (Pubitemid 40192732)
17. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost: 1995; 74 4 1185 1190
18. Exner T, Triplett DA, Taberner D, Machin SJ.; SSC Subcommittee for the Standardization of Lupus Anticoagulants Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost: 1991; 65 3 320 322
19. Pengo V, Tripodi A, Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
20. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol: 1991; 44 885 889
21. Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology: 1999; 31 2 142 147 (Pubitemid 29264060)
22. Bertolaccini ML, Hughes GR, Khamashta MA. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Clin Lab: 2004; 50 11-12 653 665 (Pubitemid 39549527)
23. Rand JH, Wu XX, Andree HA., et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulanto" phenomenon. Blood: 1998; 92 5 1652 1660 (Pubitemid 28406869)
24. Harris EN, Gharavi AE, Boey ML., et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet: 1983; 2 8361 1211 1214 (Pubitemid 14229783)
25. Gharavi AE, Harris EN, Asherson RA, Hughes GR. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis: 1987; 46 1 1 6 (Pubitemid 17225122)
26. Mouritsen S, Hier-Madsen M, Wiik A, Orum O, Strandberg Pedersen N. The specificity of anti-cardiolipin antibodies from syphilis patients and from patients with systemic lupus erythematosus. Clin Exp Immunol: 1989; 76 2 178 183 (Pubitemid 19150385)
27. Harris EN, Gharavi AE, Wasley GD, Hughes GR. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis: 1988; 157 1 23 31 (Pubitemid 18037447)
28. Harris EN. Antiphospholipid antibodies. Br J Haematol: 1990; 74 1 1 9
29. Galli M, Comfurius P, Maassen C., et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet: 1990; 335 8705 1544 1547 (Pubitemid 20189625)
30. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A: 1990; 87 11 4120 4124
31. Reber G, Arvieux J, Comby E., et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hmostase et la Thrombose). Thromb Haemost: 1995; 73 3 444 452
32. Erkan D, Derksen W, Kaplan V., et al. Real world experience with antiphospholipid antibodies (APL): how stable are APL over time? Arthritis Rheum: 2004; 50 9 S67 Suppl [abstract 1]
33. De Moerloose P, Reber G, Vogel JJ. Anticardiolipin antibody determination: comparison of three ELISA assays. Clin Exp Rheumatol: 1990; 8 6 575 577
34. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol: 2002; 118 4 548 557 (Pubitemid 44698512)
35. Pierangeli SS, Gharavi AE, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol: 2001; 44 1 48 57, quiz 58-59 (Pubitemid 32156080)
36. Kutteh WH, Franklin RD. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers. Am J Obstet Gynecol: 2004; 191 2 440 448 (Pubitemid 39178696)
37. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus: 2002; 11 5 269 275 (Pubitemid 34627428)
38. Pierangeli SS, de Groot PG, Dlott J., et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus: 2011; 20 2 182 190
39. Iverson GM, Matsuura E, Victoria EJ, Cockerill KA, Linnik MD. The orientation of beta2GPI on the plate is important for the binding of anti-beta2GPI autoantibodies by ELISA. J Autoimmun: 2002; 18 4 289 297 (Pubitemid 34970053)
40. Kaplan V, Erkan D, Derksen W., et al. Real world experience with antiphospholipid antibodies (APL): how useful is anti-2glycoprotein (2GPI) test? Arthritis Rheum: 2004; 50 9 S67 Suppl [abstract 2]
41. Triplett DA, Brandt JT. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomenon. Hematol Pathol: 1988; 2 3 121 143 (Pubitemid 19045976)
42. Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med: 1987; 111 2 120 124 (Pubitemid 17015607)
43. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program. Arch Pathol Lab Med: 1991; 115 2 109 114
44. Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants. Haemostasis: 1995; 25 3 98 105
45. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wislff F. The Lupus Ratio testan interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus AnticoagulantsISLA 5. Thromb Haemost: 2000; 83 5 704 708 (Pubitemid 30248518)
46. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost: 1995; 74 6 1597 1603 (Pubitemid 26018092)
47. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem: 2003; 49 10 1608 1614 (Pubitemid 37194214)
48. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE.; UK National External Quality Assessment Scheme for Blood Coagulation Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol: 2002; 119 2 364 369 (Pubitemid 35365483)
49. Budd R, Harley E, Quarshie A., et al. A re-appraisal of the normal cut-off assignment for anticardiolipin IgM tests. J Thromb Haemost: 2006; 4 2210 2214 (Pubitemid 44400300)
50. Ruffatti A, Olivieri S, Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost: 2008; 6 10 1693 1696
51. Forastiero R, Papalardo E, Morin K., et al. Comparative evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum: 2010; 62 10 2252 10.1002/art.30015 [abstract]
52. Forastiero R, Papalardo E, Watkins M., et al. Evaluation of the performance of monoclonal and polyclonal antibody standards in different assays for the detection of antiphospholipid (aPL) antibodies: report of a wet workshop at the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum: 2010; 62 10 2251 10.1002/art.30014 [abstract]
53. Lakos G, Favaloro EJ, Harris EN., et al. International consensus guidelines on anticardiolipin and anti-2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum: 2012; 64 1 1 10
54. Pierangeli SS, Favaloro EJ, Lakos G., et al. Standards and reference materials for the anticardiolipin and anti-2glycoprotein I assays: a report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta: 2012; 413 1-2 358 360
55. Adcock DM, Hoefner DM, Kottke-Marchant K, Marlar RA, Szamosi DI, Warunek DJ. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guidelinefifth edition. CLSI document H21-A5. Wayne (PA) Clinical and Laboratory Standards Institute: 2008
56. Lewis DA, Pound ML, Ortel TL. The reactivity of paired plasma and serum samples are comparable in the anticardiolipin and anti-2-glycoprotein-1 ELISAs. J Thromb Haemost: 2006; 4 1 265 267
57. Hasselaar P, Triplett DA, LaRue A., et al. Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol: 1990; 17 2 186 191 (Pubitemid 20108221)
58. Brey RL, Cote SA, McGlasson DL, Triplett DA, Barna LK. Effects of repeated freeze-thaw cycles on anticardiolipin antibody immunoreactivity. Am J Clin Pathol: 1994; 102 5 586 588 (Pubitemid 24337549)
59. Bertolaccini ML, Amengual O, Atsumi T., et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus: 2011; 20 2 191 205
60. Sammaritano LR, Lockshin MD, Gharavi AE. Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus: 1992; 1 2 83 90
61. Chamley LW, Pattison NS, McKay EJ. Anomalous anticardiolipin antibody results may be due to cofactor variability. Am J Hematol: 1991; 37 4 289
62. Schlame M, Haller I, Sammaritano LR, Blanck TJ. Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies. Thromb Haemost: 2001; 86 6 1475 1482 (Pubitemid 34007521)
63. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med: 1994; 179 2 457 462 (Pubitemid 24058733)
64. Roubey RA, Eisenberg RA, Harper MF, Winfield JB. " Anticardiolipino" autoantibodies recognize 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol: 1995; 154 2 954 960
65. DE Moerloose P, Reber G, Musial J, Arnout J. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost: 2010; 8 7 1540 1546
66. Findlay JW, Dillard RF. Appropriate calibration curve fitting in ligand binding assays. AAPS J: 2007; 9 2 E260 E267
67. Vesper HW, Thienpont LM. Traceability in laboratory medicine. Clin Chem: 2009; 55 6 1067 1075
68. Westgard JO. Use and interpretation of common statistical tests in method comparison studies. Clin Chem: 2008; 54 3 612
69. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc: 2008; 3 5 840 848 (Pubitemid 351639028)
70. Tholen DW, Kroll M, Astles JR., et al. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI/NCCLS document EP6-A. Wayne (PA) Clinical and Laboratory Standards Institute: 2003
71. Carey RN, Anderson FP, George H., et al. User verification of performance for precision and trueness; approved guidelinesecond edition. CLSI document EP15-A2. Wayne (PA) Clinical and Laboratory Standards Institute: 2005
72. Wong RC, Gillis D, Adelstein S., et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology: 2004; 36 1 63 68 (Pubitemid 38223415)
73. Wong RC, Favaloro EJ, Adelstein S., et al. Consensus guidelines on anti- 2 glycoprotein I testing and reporting. Pathology: 2008; 40 1 58 63 (Pubitemid 350172955)
74. Tincani A, Allegri F, Balestrieri G., et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res: 2004; 114 5-6 553 558 (Pubitemid 39422591)
75. Horowitz GL, Altaie S, Boyd JC., et al. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guidelinethird edition. CLSI document C28-A3. Wayne (PA) Clinical and Laboratory Standard Institute: 2008
76. Lakos G, Teodorescu M. IgM, but not IgA rheumatoid factor interferes with anti-cardiolipin and anti2 glycoprotein I measurements: a quantitative analysis. Lupus: 2011; 20 6 614 619
77. Hlatky MA, Greenland P, Arnett DK., et al. American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation: 2009; 119 17 2408 2416
78. Otomo K, Atsumi T, Amengual O., et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64(2):504-512.
79. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost: 2005; 93 6 1147 1152 (Pubitemid 40823521)
80. Pengo V, Biasiolo A, Gresele P., et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol: 2007; 27 12 e309 e310 (Pubitemid 350158938)
81. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost: 2005; 3 9 1993 1997 (Pubitemid 43086056)
82. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood: 2003; 101 5 1827 1832 (Pubitemid 36237580)
83. Pengo V, Ruffatti A, Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost: 2010; 8 2 237 242
84. Pengo V, Ruffatti A, Legnani C., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood: 2011; 118 17 4714 4718
85. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A: 1998; 95 26 15542 15546 (Pubitemid 29018735)
86. Iverson GM, Reddel S, Victoria EJ., et al. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol: 2002; 169 12 7097 7103 (Pubitemid 36899298)
87. Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum: 2007; 56 1 280 290 (Pubitemid 46106202)
88. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood: 2005; 105 4 1540 1545 (Pubitemid 40223671)
89. de Laat B, Pengo V, Pabinger I., et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost: 2009; 7 11 1767 1773
90. Ioannou Y, Romay-Penabad Z, Pericleous C., et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept. J Thromb Haemost: 2009; 7 5 833 842
91. Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost: 1995; 74 4 1120 1125
92. Pengo V, Biasiolo A, Brocco T, Tonetto S, Ruffatti A. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost: 1996; 75 5 721 724 (Pubitemid 26181539)
93. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost: 1997; 78 3 1008 1014 (Pubitemid 27417292)
94. Tincani A, Morozzi G, Afeltra A., et al. Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) Antiprothrombin antibodies: a comparative analysis of homemade and commercial methods. A collaborative study by the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA). Clin Exp Rheumatol: 2007; 25 2 268 274 (Pubitemid 46851430)
95. Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost: 1996; 75 3 456 459 (Pubitemid 26099711)
96. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost: 2005; 93 2 289 297 (Pubitemid 40253734)
97. Forastiero R, Martinuzzo M, Pombo G., et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost: 2005; 3 6 1231 1238 (Pubitemid 41725247)
98. Bizzaro N, Ghirardello A, Zampieri S., et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost: 2007; 5 6 1158 1164 (Pubitemid 46902116)
99. Forastiero R, Martinuzzo M, Iglesias Varela ML, Cerrato G. Multiple (triple or quadruple) aPL positivity is much more prevalent in patients with definite antiphospholipid syndrome. Lupus: 2010; 19 C109 (abstract)
100. Atsumi T, Ieko M, Bertolaccini ML., et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum: 2000; 43 9 1982 1993
101. Binder W, Lewis S, Shums Z. Clinical significance of IgG and IgM autoantibodies that target the complex of phosphatidylserine and prothrombin. Lupus: 2010; 19 C134 (abstract)
102. Branch DW, Silver R, Pierangeli S, van Leeuwen I, Harris EN. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol: 1997; 89 4 549 555 (Pubitemid 27133528)
103. Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GRV. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. Br J Rheumatol: 1998; 37 11 1229 1232
104. Fialov L, Mikulkov L, Matous-Malbohan I, Benesov O, Zwinger A. Prevalence of various antiphospholipid antibodies in pregnant women. Physiol Res: 2000; 49 3 299 305 (Pubitemid 30648887)
105. Amoroso A, Mitterhofer AP, Del Porto F., et al. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus. Hum Immunol: 2003; 64 2 265 273 (Pubitemid 36197355)
106. Matzner W, Chong P, Xu G, Ching W. Characterization of antiphospholipid antibodies in women with recurrent spontaneous abortions. J Reprod Med: 1994; 39 1 27 30 (Pubitemid 24048370)
107. Gilman-Sachs A, Lubinski J, Beer AE, Brend S, Beaman KD. Patterns of anti-phospholipid antibody specificities. J Clin Lab Immunol: 1991; 35 2 83 88
108. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertil Steril: 1996; 66 4 540 546 (Pubitemid 26315154)
109. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod: 1997; 56 1 50 58 (Pubitemid 27024161)
110. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol: 2003; 101 6 1333 1344 (Pubitemid 36694363)
111. Rand JH, Wu XX, Quinn AS., et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol: 2003; 163 3 1193 1200 (Pubitemid 37040155)
112. Hanly JG, Smith SA. Anti-beta2-glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome. Clin Exp Immunol: 2000; 120 3 537 543 (Pubitemid 30365562)
113. Gaspersic N, Ambrozic A, Bozic B, Majhenc J, Svetina S, Rozman B. Annexin A5 binding to giant phospholipid vesicles is differentially affected by anti-beta2-glycoprotein I and anti-annexin A5 antibodies. Rheumatology (Oxford): 2007; 46 1 81 86 (Pubitemid 44932790)
114. Tomer A, Bar-Lev S, Fleisher S, Shenkman B, Friger M, Abu-Shakra M. Antiphospholipid antibody syndrome: the flow cytometric annexin A5 competition assay as a diagnostic tool. Br J Haematol: 2007; 139 1 113 120 (Pubitemid 47389926)
115. Rand JH, Wu XX, Lapinski R., et al. Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood: 2004; 104 9 2783 2790 (Pubitemid 39434962)
116. de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood: 2007; 109 4 1490 1494 (Pubitemid 46239580)
117. Rand JH, Arslan AA, Wu XX., et al. Reduction of circulating annexin A5 levels and resistance to annexin A5 anticoagulant activity in women with recurrent spontaneous pregnancy losses. Am J Obstet Gynecol: 2006; 194 1 182 188 (Pubitemid 43017794)
118. Gris JC, Qur I, Sanmarco M., et al. The Nimes Obstetricians and Haematologists Study - NOHA Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nmes Obstetricians and Haematologists StudyNOHA. Thromb Haemost: 2000; 84 2 228 236 (Pubitemid 30601468)
119. Sugi T, Matsubayashi H, Inomo A, Dan L, Makino T. Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss. J Obstet Gynaecol Res: 2004; 30 4 326 332 (Pubitemid 39108450)
120. Sanmarco M, Gayet S, Alessi MC., et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost: 2007; 97 6 949 954 (Pubitemid 46939208)
121. Sanmarco M. ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods: 2010; 358 1-2 9 16